Medacta Group SA (LON:0A05)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 2.55B +8.9% |
| Revenue (ttm) | 596.55M +15.8% |
| Net Income | 83.28M +31.0% |
| EPS | 4.17 +31.0% |
| Shares Out | n/a |
| PE Ratio | 30.60 |
| Forward PE | 27.84 |
| Dividend | 1.04 (0.73%) |
| Ex-Dividend Date | May 7, 2026 |
| Volume | 899 |
| Average Volume | 5,128 |
| Open | 136.00 |
| Previous Close | 135.20 |
| Day's Range | 133.20 - 136.40 |
| 52-Week Range | 128.40 - 176.60 |
| Beta | 1.00 |
| RSI | 30.57 |
| Earnings Date | Sep 9, 2026 |
About Medacta Group
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland. [Read more]
Financial Performance
In 2025, Medacta Group's revenue was 683.83 million, an increase of 15.79% compared to the previous year's 590.58 million. Earnings were 95.46 million, an increase of 30.97%.
Financial numbers in EUR Financial StatementsNews
Medacta Group price target raised to CHF 185 from CHF 182 at Berenberg
Berenberg raised the firm’s price target on Medacta Group (MEDGF) to CHF 185 from CHF 182 and keeps a Buy rating on the shares.
Medacta Group SA (XSWX:MOVE) Full Year 2025 Earnings Call Highlights: Robust Growth and ...
Medacta Group SA (XSWX:MOVE) Full Year 2025 Earnings Call Highlights: Robust Growth and Strategic Investments
Full Year 2025 Medacta Group SA Earnings Call Transcript
Full Year 2025 Medacta Group SA Earnings Call Transcript
Medacta Group Earnings Call Transcript: H2 2025
Revenue grew 18.5% in constant currency to EUR 684 million, with net profit up 31% to EUR 95.5 million and a proposed 60% dividend increase. 2026 guidance targets 10%-14% revenue growth and gradual margin expansion, supported by innovation and global expansion.
Medacta Group Earnings Call Transcript: Q4 2025
Revenue grew 18.5% in constant currency, exceeding guidance, with strong performance across all regions and business lines. Knee sales surpassed hip for the first time, and the Parcus acquisition boosted extremities. FX headwinds in APAC and a U.S. spine sales transition were noted.
Medacta Group price target raised to CHF 182 from CHF 175 at Berenberg
Berenberg analyst Sam England raised the firm’s price target on Medacta Group (MEDGF) to CHF 182 from CHF 175 and keeps a Buy rating on the shares. Published first on
Medacta Group price target raised to CHF 175 from CHF 160 at Berenberg
Berenberg analyst Sam England raised the firm’s price target on Medacta Group (MEDGF) to CHF 175 from CHF 160 and keeps a Buy rating on the shares. Published first on
Medacta Group price target raised to CHF 161 from CHF 159 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 161 from CHF 159 and keeps an Overweight rating on the shares.
Medacta Group Earnings Call Transcript: H1 2025
H1 2025 saw revenue up 19.8% and net profit up 58% year-over-year, with all business lines and geographies delivering strong, above-market growth. Adjusted EBITDA margin rose to 29.6%, and guidance for 2025 targets 16–18% revenue growth and a 28% margin.
Medacta Group downgraded to Neutral from Buy at UBS
UBS downgraded Medacta Group (MEDGF) to Neutral from Buy with a price target of CHF 151, up from CHF 141. The company’s revenue growth now looks fully priced into the
Medacta Group price target raised to CHF 159 from CHF 146 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 159 from CHF 146 and keeps an Overweight rating on the shares.
Medacta Group Earnings Call Transcript: H1 2025
H1 2025 revenue grew nearly 20% year-over-year, with strong performance across all regions and product lines. Upgraded 2025 and midterm guidance reflects sustained momentum, robust innovation, and no tariff impact, supported by strong cash flow and low leverage.
Medacta Group price target raised to CHF 146 from CHF 136 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 146 from CHF 136 and keeps an Overweight rating on the shares.
Medacta Group Earnings Call Transcript: H2 2024
Revenue grew 16% to over EUR 590 million, with net profit up 54% and a 28% EBITDA margin. All segments outperformed the market, and 2025 guidance targets 13%-15% revenue growth and 27% EBITDA margin, including the Parcus acquisition.
Medacta Group price target raised to CHF 160 from CHF 150 at Berenberg
Berenberg raised the firm’s price target on Medacta Group (MEDGF) to CHF 160 from CHF 150 and keeps a Buy rating on the shares.
Medacta Group price target raised to CHF 136 from CHF 135 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Medacta Group (MEDGF) to CHF 136 from CHF 135 and keeps an Overweight rating on the shares. Published first…
Medacta Group Earnings Call Transcript: H2 2024
Revenue grew 16.2% to €590.6M in 2024, led by strong innovation in knees, extremities, and spine. SpheriKA and NextAR technologies drove segment outperformance, with robust growth in North America and ASCs. Tariff risks are manageable, and momentum is expected to continue.
Medacta Group upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Medacta Group (MEDGF) to Overweight from Equal Weight with a CHF 135 price target The firm also upgrade the medical technology sector view to Attractive from In-line.
Medacta Group Transcript: H1 & CMD 2024
H1 2024 saw 14.6% revenue growth, strong gains in knees and shoulders, and a 30% net profit increase. Guidance targets 13%-15% top-line growth for 2024 and low double-digit CAGR through 2027, with margins stable and CapEx closely tied to growth.
Medacta Group Earnings Call Transcript: H1 2024
H1 2024 saw 14.3% constant currency revenue growth, led by strong Knee and Shoulder performance and robust gains in Europe, APAC, and North America. Guidance for 13%-15% growth is confirmed, with a strong H2 pipeline expected from recent marketing and education investments.
Medacta Group assumed with an Equal Weight at Morgan Stanley
Morgan Stanley assumed coverage of Medacta Group with an Equal Weight rating and CHF 134 price target.
Medacta Group price target raised to CHF 130 from CHF 125 at Morgan Stanley
Morgan Stanley analyst Robert Davies raised the firm’s price target on Medacta Group to CHF 130 from CHF 125 and keeps an Equal Weight rating on the shares. Published first…
Medacta Group Earnings Call Transcript: H2 2023
Medacta Group Earnings Call Transcript: H2 2023
Medacta Group initiated with a Buy at Berenberg
Berenberg initiated coverage of Medacta Group with a Buy rating and CHF 150 price target. The firm’s channel checks with surgeons and industry executives have given it confidence that the…